Johnson & Johnson

JNJ-N

NYSE:JNJ

147.55
0.85 (0.57%)
Johnson & Johnson is an American multinational medical devices, pharmaceutical and consumer packaged goods manufacturing company founded in 1886.
More at Wikipedia

Analysis and Opinions about JNJ-N

Signal
Opinion
Expert
BUY
BUY
January 10, 2019
Would the hiccup they had with the baby powder be a problem for the company and it is safe to step in? - Still own this company. They had it for a couple of years. The company said the product is safe and they said that the evidence is in their side. It is a triple A rated company. Their pharmaceutical division is doing very well. The dividend is very attractive and with the pullback it is good to step in.
Show full opinionHide full opinion
Johnson & Johnson (JNJ-N)
January 10, 2019
Would the hiccup they had with the baby powder be a problem for the company and it is safe to step in? - Still own this company. They had it for a couple of years. The company said the product is safe and they said that the evidence is in their side. It is a triple A rated company. Their pharmaceutical division is doing very well. The dividend is very attractive and with the pullback it is good to step in.
BUY WEAKNESS
BUY WEAKNESS
December 20, 2018
One of the biggest companies in the world. Pharama and consumer products. They were hit with a multi-billion dollar law suit that their baby powder has chemicals in it rather than just talc.
Show full opinionHide full opinion
Johnson & Johnson (JNJ-N)
December 20, 2018
One of the biggest companies in the world. Pharama and consumer products. They were hit with a multi-billion dollar law suit that their baby powder has chemicals in it rather than just talc.
DON'T BUY
DON'T BUY
December 19, 2018
It is suffering from asbestos in their talcum powder. This issue goes back four decades. The company is doing major damage control and he is not sure how it will end up. He would stay way.
Show full opinionHide full opinion
Johnson & Johnson (JNJ-N)
December 19, 2018
It is suffering from asbestos in their talcum powder. This issue goes back four decades. The company is doing major damage control and he is not sure how it will end up. He would stay way.
BUY
BUY
December 13, 2018
This is a portfolio anchor type of company. It is defensive and pays a great dividend for a US equity. If you want to make a bet on Pharma you would not use this one because there are two other businesses in there. These other two businesses give it some diversification. It is a good long term play.
Show full opinionHide full opinion
Johnson & Johnson (JNJ-N)
December 13, 2018
This is a portfolio anchor type of company. It is defensive and pays a great dividend for a US equity. If you want to make a bet on Pharma you would not use this one because there are two other businesses in there. These other two businesses give it some diversification. It is a good long term play.
HOLD
HOLD
November 16, 2018
Worries about if markets do sell off. It’s had a great run up. It would have to get above levels it’s at. He’d buy because it’s still trending higher, but with the caveat to be careful with the DOW and S&P if they start to sell off.
Show full opinionHide full opinion
Johnson & Johnson (JNJ-N)
November 16, 2018
Worries about if markets do sell off. It’s had a great run up. It would have to get above levels it’s at. He’d buy because it’s still trending higher, but with the caveat to be careful with the DOW and S&P if they start to sell off.
COMMENT
COMMENT
November 12, 2018
Avoided today's sell-off. Chart has a fantastic uptrend since 2014, though it's been oversold and overbought in periods. Current price is just below its January peak. This year it has a cup and handle pattern, which is good. It's not testing its January high. JNJ come be a defensive play, or it could go sideways or even drift down.
Show full opinionHide full opinion
Johnson & Johnson (JNJ-N)
November 12, 2018
Avoided today's sell-off. Chart has a fantastic uptrend since 2014, though it's been oversold and overbought in periods. Current price is just below its January peak. This year it has a cup and handle pattern, which is good. It's not testing its January high. JNJ come be a defensive play, or it could go sideways or even drift down.
HOLD
HOLD
November 9, 2018
He is overweight in both pharmaceuticals and biotechnology. It is nearing a 52 week high. They have continuously raised the dividend. It is a defensive name. There are other names in this sector that he prefers.
Show full opinionHide full opinion
Johnson & Johnson (JNJ-N)
November 9, 2018
He is overweight in both pharmaceuticals and biotechnology. It is nearing a 52 week high. They have continuously raised the dividend. It is a defensive name. There are other names in this sector that he prefers.
WEAK BUY
WEAK BUY
October 23, 2018

Healthcare names are defensive and a portfolio needs them, but JNJ is flat YTD. If your portfolio is light in defensive names, then consider this. Buy according to your overall portfolio composition. Consumer and medical product
divisions have modest growth. Pharma is its big driver of growth.

Show full opinionHide full opinion
Johnson & Johnson (JNJ-N)
October 23, 2018

Healthcare names are defensive and a portfolio needs them, but JNJ is flat YTD. If your portfolio is light in defensive names, then consider this. Buy according to your overall portfolio composition. Consumer and medical product
divisions have modest growth. Pharma is its big driver of growth.

BUY
BUY
October 11, 2018

Great company. Pharma, medical devices and consumer are their 3 divisions, which makes them unique--that diversification serves them well, unlike phrama companies depend solely on their pharma division. Has raised dividend for 54 years. Well run.

Show full opinionHide full opinion
Johnson & Johnson (JNJ-N)
October 11, 2018

Great company. Pharma, medical devices and consumer are their 3 divisions, which makes them unique--that diversification serves them well, unlike phrama companies depend solely on their pharma division. Has raised dividend for 54 years. Well run.

PAST TOP PICK
PAST TOP PICK
October 10, 2018

(Past Top Pick Oct.10, 2017,Up 10%) Their pharma is doing quite well. All health companies are facing patent losses, but J&J is positioned to weather this, because they're launching 10 new drugs in the next 18 months. In this defensive
environment, this should hold up well. Have been increasing their dividend for 56 years, now paying a 2.5% yield.

Show full opinionHide full opinion
Johnson & Johnson (JNJ-N)
October 10, 2018

(Past Top Pick Oct.10, 2017,Up 10%) Their pharma is doing quite well. All health companies are facing patent losses, but J&J is positioned to weather this, because they're launching 10 new drugs in the next 18 months. In this defensive
environment, this should hold up well. Have been increasing their dividend for 56 years, now paying a 2.5% yield.

BUY
BUY
August 30, 2018

He loves it. The judgment against them is not significant. He has a model price of $160.81, a 20% upside. It is in the top 100 of the S&P 500 - it is US and priced in US Dollars – all the things he loves.

Show full opinionHide full opinion

He loves it. The judgment against them is not significant. He has a model price of $160.81, a 20% upside. It is in the top 100 of the S&P 500 - it is US and priced in US Dollars – all the things he loves.

COMMENT
COMMENT
August 27, 2018

Trading at a high mulitple, but has tranditioned well from the consumer space to heathcare. It's well-positioned for international growth, but the rising US dollar is a headwind. Market performance is the best you'll get from J&J.

Show full opinionHide full opinion

Trading at a high mulitple, but has tranditioned well from the consumer space to heathcare. It's well-positioned for international growth, but the rising US dollar is a headwind. Market performance is the best you'll get from J&J.

TOP PICK
TOP PICK
July 10, 2018

Their stock has done nothing this year, partially because of pricing pressure from Donald Trump. She thinks their pharma division is doing well, with lots of new products and a good pipeline. They have identified 10 drugs that have a $1 billion potential. This company spends 13% of revenues on R&D, which shows a serious level of investment in the future. They have also made some acquisitions to go into new areas. They have increased their dividend consistently for over 50 years. (Analysts’ price target is $143.29)

Show full opinionHide full opinion

Their stock has done nothing this year, partially because of pricing pressure from Donald Trump. She thinks their pharma division is doing well, with lots of new products and a good pipeline. They have identified 10 drugs that have a $1 billion potential. This company spends 13% of revenues on R&D, which shows a serious level of investment in the future. They have also made some acquisitions to go into new areas. They have increased their dividend consistently for over 50 years. (Analysts’ price target is $143.29)

BUY
BUY
June 7, 2018

It is a very well run company. Pharma, medical supply and personal goods businesses. The pharma business is doing well. They have a number of drugs. Brands are not as valued by millennials as by their predecessors. This is the struggle that JNJ-N is having. They have a strong balance sheet and a nice dividend.

Show full opinionHide full opinion

It is a very well run company. Pharma, medical supply and personal goods businesses. The pharma business is doing well. They have a number of drugs. Brands are not as valued by millennials as by their predecessors. This is the struggle that JNJ-N is having. They have a strong balance sheet and a nice dividend.

PAST TOP PICK
PAST TOP PICK
May 8, 2018

(Past Top Pick on May 16, 2017, Down 1.5%) Their pharma side and newly released drugs are doing very well which offsets their drugs that are going generic. They have a solid pipeline of 10 new drugs over the next few years, each drug expected to make $1-billion. They invest in R&D and buy companies occasionally, including one last year. Yield under 3%.

Show full opinionHide full opinion

(Past Top Pick on May 16, 2017, Down 1.5%) Their pharma side and newly released drugs are doing very well which offsets their drugs that are going generic. They have a solid pipeline of 10 new drugs over the next few years, each drug expected to make $1-billion. They invest in R&D and buy companies occasionally, including one last year. Yield under 3%.

Showing 46 to 60 of 450 entries